Status:
UNKNOWN
Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Portal Hypertension
Eligibility:
All Genders
18-80 years
Brief Summary
Complications associated with portal hypertension are the leading cause of death in patients with cirrhosis. Until now, hepatic venous pressure gradient (HVPG) - the difference between the wedged hepa...
Eligibility Criteria
Inclusion
- Patients with viral cirrhosis were diagnosed;
- Age 18-80 years;
- Need and willing to accept measure HVPG;
- First HVPG measurement of more than 5 mmHg;
- Signed Informed Consent
Exclusion
- Patients with viral cirrhosis have been treated with antiviral therapy and have achieved virological response;
- Ready to accept or have accepted a TIPS procedure;
- Splenic embolization was performed;
- Inaccurate measurement of HVPG due to combined hepatic venous shunt;
- Complicated with alcoholic liver disease, autoimmune liver disease or other types of liver disease;
- Complicated with liver cancer or other organ malignancy;
- Combined with severe cardiopulmonary disease affects survival;
- Complicated with severe renal insufficiency;
- Concomitant portal vein cavernous degeneration or extensive portal vein thrombosis;
- Women who are planning to become pregnant or who are pregnant or breastfeeding.
Key Trial Info
Start Date :
March 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04797910
Start Date
March 10 2021
End Date
December 31 2022
Last Update
March 15 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.